| Names | |
|---|---|
| Preferred IUPAC name | 1-Cyclopropyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid hydrochloride |
| Other names | Levaquin Tavanic Loxof Levoday Quixin |
| Pronunciation | /ˌliːvəˈflɒksəˌsɪn haɪˌdrɒklaɪd ˈkæpsjuːlz/ |
| Identifiers | |
| CAS Number | 177325-13-2 |
| 3D model (JSmol) | `load =1orc` |
| Beilstein Reference | 3930443 |
| ChEBI | CHEBI:63599 |
| ChEMBL | CHEMBL539 |
| ChemSpider | 143550 |
| DrugBank | DB01137 |
| ECHA InfoCard | echa.europa.eu/infocard/100900008921 |
| EC Number | 625-37-6 |
| Gmelin Reference | Gmelin Reference: 833715 |
| KEGG | D08148 |
| MeSH | D046361 |
| PubChem CID | 123631 |
| RTECS number | QJQ0639DXL |
| UNII | D8V90J12SE |
| UN number | UN3248 |
| CompTox Dashboard (EPA) | DTXSID7085275 |
| Properties | |
| Chemical formula | C18H20FN3O4·HCl |
| Molar mass | 415.85 g/mol |
| Appearance | Capsules are white or off-white, with "LFX" printed on the capsule shell. |
| Odor | Odorless |
| Density | 0.5g/capsule |
| Solubility in water | Freely soluble in water |
| log P | -0.41 |
| Acidity (pKa) | -6.09 |
| Basicity (pKb) | 6.3 |
| Dipole moment | 2.06 D |
| Pharmacology | |
| ATC code | J01MA12 |
| Hazards | |
| Main hazards | May cause allergic reactions, tendon rupture, nerve damage, serious mood or behavior changes, and may worsen muscle weakness in people with myasthenia gravis. |
| GHS labelling | GHS07, GHS08, Warning, May cause respiratory irritation, May cause an allergic skin reaction, May cause long lasting harmful effects to aquatic life |
| Pictograms | Capsule, Oral Use, Prescription Only, Keep Out of Reach of Children, Store Below 25°C |
| Signal word | Warning |
| Hazard statements | Hazard statements: Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | Protect from light, Keep out of reach of children |
| Lethal dose or concentration | LD50 (oral, rat): >1500 mg/kg |
| LD50 (median dose) | levofloxacin hydrochloride LD50 (oral, rat): 1,640 mg/kg |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 500mg |
| Related compounds | |
| Related compounds | Levofloxacin Levofloxacin Hemihydrate Levofloxacin Hydrate Levofloxacin Mesylate Levofloxacin Lactate |
| Product Name & IUPAC Name |
Product Name: Levofloxacin Hydrochloride Capsules IUPAC Name: (−)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid monohydrochloride, hemihydrate (for the API form used in capsule preparation) |
|---|---|
| Chemical Formula | C18H20FN3O4·HCl·0.5H2O (API reference used for encapsulation; excipients not included in formula) |
| Synonyms & Trade Names |
Synonyms: (-)-Levofloxacin HCl, Levofloxacin hydrochloride hemihydrate, Levofloxacin capsules (formulation includes HCl salt) Trade Names: Varying by market authorization holder and region. Common: Tavanic, Levaquin (brand names reference varied regional registration; finished dosage custom-branded by downstream partners). |
| HS Code & Customs Classification |
HS Code: 3004.20 (Customs formalities rely on finished formulation: "Medicaments containing antibiotics, put up in measured doses for retail sale") HS classification requires regulatory-compliant declaration of finished dosage. Upstream API falls under 2941.40, but export of capsule product triggers finished dosage-specific controls, validation, and certificate of pharmaceutical product review prior to clearance. |
Our technical, quality, and production departments maintain full traceability from raw material input (levofloxacin API) through to filled and tested capsule output. The specification for capsule content, shell composition, disintegration, and uniformity draws from both global pharmacopoeia compliance and client submission requirements. Differences between customers’ regions can lead to changes in excipient systems or encapsulation standards, which may affect release testing and customs documentation.
The selection of levofloxacin HCl as the salt form remains driven by processability and bioavailability targeting. Every encapsulation batch tracks impurity levels, residual solvent profiles, and in-process blend uniformity, applying process analytical control at key steps – pre-blend, post-blend, and final fill. API grade, water activity, and blend flow properties become critical for consistent capsule fill-weight and dissolution rate across lots.
For customs and regulatory documentation, harmonized system code selection must strictly reflect the scope (API versus finished dose versus bulk packed for downstream fill), particularly as varying HS-classification impacts certificate requirements and logistical lead times at export. Any deviation or misclassification can trigger clearance delays or require corrective shipments and technical justifications.
Levofloxacin Hydrochloride Capsules typically contain off-white to yellowish, odorless powder formatted into hard gelatin capsules for oral administration. The precise color tone and capsule shell depend on excipient selection and the encapsulation process. Production batches may show slight variability in shade due to the capsule’s polymer composition and dye.
Melting point and boiling point measurements for levofloxacin hydrochloride as a raw material are referenced during API handling, but finished capsules are not subjected to volatility or ignition testing since oral solid dosing is not at risk for flash or vaporization events at ambient conditions encountered in supply chains.
Capsule density varies with fill weight, excipient blend, and capsule size/type. Manufacturers can adjust bulk density via granulation and blending strategy to support processability during filling and to control dosage uniformity.
This substance shows good chemical stability under dry, protected conditions. Most grades are sensitive to light and humidity, so the production process includes steps to minimize exposure. Formulations react if mixed with strong oxidizers or acids during excipient blending, so control of excipient compatibility is reviewed at process scale-up. Stability depends on the chosen API source, excipient grade, and whether additional stabilizing agents are employed.
Levofloxacin hydrochloride demonstrates high aqueous solubility, which aids in rapid disintegration and dissolution in gastrointestinal fluid. Manufacturers confirm solubility during development and monitor for precipitation or crystallization in pilot-scale batches. Precise dissolution kinetics can differ between grades due to microcrystalline size and excipient hydration effects. Solution prep is only performed for analytical QC purposes; capsule fill is handled in the solid state.
| Attribute | Pharma Grade | Customized Grade |
|---|---|---|
| Assay (Levofloxacin Content) | Grade-dependent, typically confirmed by HPLC | Defined per client specification |
| Moisture Content | Monitored as per pharmacopeial standards | Adjusted as needed for downstream formulation |
| Impurity Limits | Follows major pharmacopeias (e.g., EP, USP) | May be specified more tightly for certain clients |
Profiled impurities arise from the synthesis route and raw material purity. Most common process-derived impurities include unreacted starting material, epimers, and related substances. The impurity threshold and identification depend on pharmacopoeial monograph selected by the client, and internal control limits may be more stringent for regulated export markets. Impurity quantification is performed by HPLC or LC-MS, with product rejected at batch release if any single or total impurity exceeds the contractual specification.
HPLC is used for assay, impurities, and dissolution. Water content is measured by Karl Fischer or LOD method. Capsule integrity and uniformity are controlled by pharmacopeial testing. Standards for physical tests and microbiological QC match those prescribed by the market of sale—USP, EP, ChP, or customer-specified monograph.
API levofloxacin hydrochloride is sourced from GMP-certified facilities with full traceability of quinolone intermediates. Capsule-grade excipients include microcrystalline cellulose, magnesium stearate, and suitable disintegrants, qualified to pharmacopoeia. All incoming raw materials are sampled and tested for identity and quality on arrival per SOP.
The API is typically synthesized via condensation of appropriate fluorinated quinolone intermediates, followed by resolution and hydrochloride salt formation. Each route is selected for impurity minimization and yield efficiency. Main side-reactions create ciprofloxacin-related impurities; strict temperature and pH control curbs over-chlorination and degradation.
At the capsule plant, blending and encapsulation use validated batch protocols, with in-process checks for particle size, blend uniformity, and fill weight. API purity is confirmed before use, minimizing risk of batch recalls for sub-spec capsules. The purification of intermediates is handled upstream at the API plant, prior to final blending.
Batch samples undergo full release testing against internal and market-specific standards. This includes identity, assay, impurity screening, microbiological limit tests, and dissolution. Batch release is gated by compliance to release criteria, with all results archived per GMP record-keeping rules.
Under strong acid or base, levofloxacin hydrochloride may undergo hydrolysis or epimerization. Amide formation or salt exchange is possible only under laboratory conditions; such modifications are not standard in manufacturing but are considered for custom derivatives.
Reaction parameters (such as catalyst, solvent, and temperature) depend on the stage—API synthesis may use aqueous or organic solvents, and precise control is maintained to prevent unwanted substitution on the quinolone ring. Downstream processing does not ordinarily involve further chemical transformation post-API formation.
Modification potential includes esterification or different salt formation for alternative dosage forms. These adjustments must be separately validated for each use case and regulatory market.
Capsule batches require storage in cool, dry, and light-protected environments. Standard protocols use climate-controlled warehouses, with humidity and temperature monitoring according to GMP. Exposure to elevated humidity or strong light causes hydrolysis or color changes.
HDPE bottles or alu-alu blisters provide sufficient barrier from moisture and oxygen. The choice of container depends on destination market shipping requirements and product shelf life targets. Repacking from transport packaging to unit-dose packaging is only performed under cleanroom conditions.
Shelf life is set based on ongoing stability studies for each lot and packaging type. Degradation manifests as loss of assay, increased impurities, or visible color changes. Batches failing ongoing or annual stability assessment get flagged for investigation and hold-release procedures.
Risk phrases and hazard classification for levofloxacin hydrochloride are established based on GHS data for quinolone antibiotics; the final labeling aligns with handling risk and regulatory jurisdiction. Capsule formulation reduces exposure risk versus active bulk.
Production and packaging workers follow written SOPs for dust containment, use of gloves and respiratory protection, and prompt cleanup of spills. The facility enforces access limits and environmental monitoring for airborne API during filling.
Toxicological assessment is based on human and preclinical studies for oral administration; all personnel consult regulatory-approved safety references. No intentional testing of pure API toxicity on site, but accidental oral or dermal exposure procedures are trained routinely.
Operators in blending and encapsulation areas use closed systems and personal protective equipment. Occupational exposure levels depend on the regulatory authority and are periodically reviewed based on published updates. Spill and cleanup procedure protocols are documented and enforced, with all waste handled per hazardous pharmaceutical waste guidelines.
Levofloxacin Hydrochloride Capsule manufacturing capacity reflects installed synthesis, encapsulation, and final packaging resources. Actual supply capacity depends on route (enzymatic/chemical), core pharma-grade inputs, process reliability, and batch release timing. Production lines for regulated-market and generic-market grades run on parallel scheduling, subject to GMP requirements and regular audits. Production availability typically adjusts seasonally with maintenance scheduling, order backlog, and regulatory batch holds. Capacity utilization varies: higher spec, US/EU-marketed capsules rely on different validation lots and cleaning protocols compared to India-standard generics.
Standard lead times range according to validation backlog, grade, and batch size. Orders destined for US or EU require additional QP release or audit clearance, extending lead times. MOQ is often determined by capsule fill line batch size (e.g., for 250 mg/500 mg), driven by both technical and regulatory minimums. Custom packaging or labeling options influence lead time and MOQ, especially if serialization or anti-counterfeiting data is required.
Blister packs, bottle packs, strip packs, and bulk capsule form are all supported, dependent on market and customer preference. For regulated economies, packaging incorporates child-resistant features, traceability-labeling, and, in some cases, cold chain protection for tropical market supply. All primary and secondary packaging demands alignment with destination pharmacopeia standards; deviations can only occur following customer-approved protocols.
Shipping methods include air and ocean freight, chosen based on shelf-life constraints, temperature stability, and destination lead time requirements. Documentation covers Certificate of Origin, GMP declarations, and, where required, import/export licenses. Payment terms differ by customer risk profile and regulatory background, ranging from advance payment for first time buyers to net billing for established, audited importers. Deviations in payment terms must be justified by credit checks, purchase volume, or market trust validation.
Levofloxacin Hydrochloride cost structures emerge from both API synthesis and encapsulation processes. Bulk API price influences the final capsule cost most heavily, linking directly to the fluoroquinolone intermediates, starting chemical costs, and consumption of critical reagents. In-process utility consumption, solvent recycling losses, and labor input round out the final cost. Excipient prices—such as microcrystalline cellulose, magnesium stearate, and capsule shell material—contribute at a smaller scale, but spike when food-grade gelatins fluctuate due to livestock market volatility.
API price fluctuates on market-driven factors: supply chain interruptions, increased compliance costs following regulatory changes, and regional feedstock shortages. Seasonal Chinese plant shutdowns and Indian freight bottlenecks often trigger API lead time surges. Anti-dumping duties on starting materials and pharma policy changes in top production regions regularly alter the raw material index, driving up or restraining downstream capsule prices.
Price differentiation reflects grade and certification. Finished pharmaceutical grade destined for US/EU/JP/IN regulatory approval carries validation and documentation surcharges compared to off-patent generic grades. Purity variation directly causes price spread: export lots tested down to known impurity sub-limits (e.g., for US FDA or EU EDQM) use different synthesis routes and may require double purification cycles, raising cost. Packaging certification (e.g., child-resistant, serialization) and country-specific serialization drive further per-unit price uplifts.
Global levofloxacin capsule supply faces upstream concentration: APAC region (notably China and India) accounts for a majority of API output. Regulatory tightening in these countries causes intermittent export slowdowns, reflected by temporary price hikes. US and EU depend on stable, GMP-validated import channels, while Japan prioritizes domestic and in-region qualification. Supply in emerging regions depends on public procurement cycles and local regulation.
The US remains a high-value market due to continued demand for oral broad-spectrum antibiotics in both hospital and outpatient settings; price ceilings imposed by generic competition. EU imports maintain stability driven by parallel import controls and local QA requirements. Japan operates with minimal API import tolerance; local production and QA pre-approval heavily influence pricing. Indian manufacturers source both locally and from China; Indian government policy on price control and excipient compliance can quickly shift the landed cost. China regulates both API and finished product pricing—environmental shutdowns have raised both compliance and production overheads.
By 2026, levofloxacin hydrochloride capsule prices will likely show moderate volatility. Raw material markets, API synthesis route improvements, and regional regulatory events will each exert strong influence. Without new major patent moves or off-patent disruption, capsule price trends follow the lead of API input dynamics. Expected incremental increases in regulatory cost, packaging compliance, and quality assurance will gradually raise the floor price. Price reduction in bulk supply may arise if China and India increase production, but government-mandated ecological and labor standards could counteract downward pressure.
Analysis draws from batch production records, periodic industry price monitoring (ICIS, ChemAnalyst), and direct supply agreements with regulatory economies. Feedback loops from disclosed tenders and actual end-user customer orders provides the most reliable uptrends or downtrends.
Recent years brought periodic production halts in China, stemming from stricter environmental controls and API plant compliance crackdowns. Indian port delays and freight cost rises since 2022 increased capsule landed cost into Africa and South America. US and European regulators raised documentation requirements for excipient traceability, leading to longer qualification periods before batch release.
The US FDA and EMA both increased scrutiny on nitrosamine and solvent residue limits from mid-2023, demanding extra analytical release checks. India’s DCGI tightened its review of imported API documentation and capsule batch records. China renewed environmental discharge standards for fluoroquinolone intermediate manufacturing this year, forcing smaller API plants to seek third-party waste management, raising operational costs.
Key suppliers responded by strengthening raw material supplier audits, investing in encapsulation automation to counter labor cost rises, and expanding in-house QC capabilities for rapid analytical verification. Batch traceability upgrades allow faster customer response on serialization. Advance batch reservation and staggered production planning minimize exposure to upstream interruptions. Dual-sourcing routes and backup warehouse expansion reduce finished product lead time overruns.
Levofloxacin Hydrochloride Capsules see use in several sectors of the pharmaceutical industry. The largest segment remains oral solid pharmaceutical dosage formulations for human health, where the requirements focus on minimizing trace-level impurities and controlling residual solvents. Some veterinary applications draw on alternative grade criteria, especially in markets with variable regulatory regimes. Across regions, major buyers specify the grade based on finished dose demands, often tightening control points for critical impurities linked to quinolone antibiotics.
| Application Field | Recommended Grade | Rationale |
|---|---|---|
| Human Pharmaceuticals (Prescription/Generic) | Pharmaceutical Grade | Purity, impurity profile, and residual solvent content must align with ICH Q3A/Q3B/Q3C recommendations. Batch-to-batch consistency and full compliance with local pharmacopoeias (such as USP, EP, JP) are sought at every step. |
| Veterinary Pharmaceuticals | Pharmaceutical or Veterinary Grade (region-specific) | In veterinary applications, regulatory standards may allow broader impurity limits. Finished product approval routes and market destination largely dictate grade. |
Assess the final use. Human pharmaceutical products call for pharmacopoeial grades and trace-level impurity profiles. Veterinary products can vary, but grade selection should always start from the destination market’s pharmaceutical regulation.
Consider the relevant compendial standards (USP, EP, JP, or local equivalents). These define maximum allowable impurity levels, identification tests, and dissolution requirements. Engage regulatory groups early if clarification is needed.
Assess downstream formulation processes. Wet granulation, direct blending, or capsule filling impose different constraints on impurity content and particle size. Specify both purity and impurity tolerances when placing grade requests.
High-volume producers often prioritize grade consolidation to simplify inventory and cost management, while smaller batch or regional needs may require custom impurity thresholds or flexible batch sizing. Budget pressures can influence raw material or process route selection.
Laboratory-scale batch evaluation almost always precedes full order placement. Sample validation runs help confirm grade compatibility with the intended formulation and identify any unforeseen excipient interactions, capsule machine stops, or out-of-spec flow properties.
Levofloxacin Hydrochloride Capsules produced within our facilities follow a traceable quality framework built on globally recognized management systems. Production lines operate under ISO-certified environments, with internal audits and reviews driven by the specifics of pharmaceutical-grade compound processing. Quality control teams routinely evaluate batch documentation against both internal and client-defined standards.
Investment in staff training and continuous monitoring of the manufacturing environment forms the basis for compliance. Critical control points—such as air quality, humidity regulation, and cross-contamination mitigation—are managed by process-specific standards. Certification maintenance includes surveillance of our environmental monitoring systems and regular update cycles directed by regulatory authority feedback.
Levofloxacin Hydrochloride Capsules qualify for product registrations and certifications where regulatory requirements dictate, such as filings with domestic and export pharmacopeias or local health authorities. Grade differentiation typically aligns with market-specific standards, with drug master files or dossiers deposited as required. Each registration process initiates a documentation package that tracks lot genealogy, analytical reports, and purification pathway details linked to routine requalification.
Test method validation stems from pharmacopeia or customer-chosen standards, adapting assay and impurity profiling requirements based on batch-to-batch data and intended application. For strict-regulated markets, certification tasks extend to process validation, serialization controls, and change notification protocols.
Full traceability through lot release documents, certificates of analysis, and stability data supports batch shipment and after-sale technical support. Documentation sets cover origin of key raw materials, processing sequence, cleaning validation, and final product conformance. Typical values for physical and chemical attributes depend on grade and contractual requirements.
Regular updates reflect any documented process change, deviation management, or requests stemming from inspection findings. For application-sensitive customers, expanded documentation packages can detail environmental controls, operator training logs, and chain-of-custody records for regulatory audits.
Forecast-based collaboration improves the alignment of supply schedules for Levofloxacin Hydrochloride Capsules. Our core manufacturing infrastructure has dedicated process lines to support long-term, repeatable output at industry-standard scales. Multi-line design and buffer inventory help mitigate unexpected market surges or supply chain disruptions.
Contract flexibility allows for annual or multi-year commitments, rolling forecast windows, and variable minimum order quantities where justified by demand pattern analysis.
Batch segmentation for Levofloxacin Hydrochloride Capsules reflects customer order patterns—smaller lots support clinical supply or product evaluation, while larger-scale batches match commercial procurement. Line configuration changes or dedicated campaign schedules are determined by process compatibility and cleaning validation intervals.
Production prioritization logic accounts for raw material lead times, documented equipment maintenance, and batch yield consistency. As a manufacturer, continual review of upstream raw material qualification helps minimize external supply risk.
Sample provision is structured around technical review, pre-contractual screening, and collaborative verification of grade suitability. Sample requests initiate a chain of technical documentation exchange, including analytical data, process description, and handling guidance. Sample size, batch reference, and associated documentation will reflect client application, regulatory territory, and specific end-use requirements.
Business models for Levofloxacin Hydrochloride Capsules adapt to project lifecycle stages. For product development or evaluation, short-term supply contracts allow customers to qualify the material under their conditions. For commercial supply, volume discounts, split delivery, and flexible reserves can be implemented within the boundaries of production lead time and raw material availability.
On request, dedicated production windows or exclusivity arrangements can be negotiated, supported by mutual data exchange and clearly defined release specifications. An ongoing technical interface supports change management, process optimization, and specification adjustment over the life of the cooperation.
Research attention remains concentrated on achieving lower residual solvent profiles, reducing genotoxic impurities, and improving crystalline forms for better flow and compaction during capsule filling. Process analytical technology is now frequently applied at multiple production points, leading to tighter particle size distribution and improved batch reproducibility. Compared to earlier years, lab efforts increasingly target bioequivalence with innovator brands in both dissolution profiles and impurity spectra.
Typical focus areas extend beyond anti-infective therapy for urinary or respiratory tract infections. Collaborative programs now investigate the utility of levofloxacin capsules in multi-drug regimens, especially in hospital-acquired infections requiring oral step-down therapy. Regulatory-driven demand for pediatric and geriatric formulations encourages the development of modified-release capsules and dose-flexible solutions, highlighting the need for versatile API-matrix compatibility studies.
Consistent low-level control of residual solvents and unreacted starting materials dictates both raw material selection and solvent recovery strategy. Moisture sensitivity impacts both storage and encapsulation, pushing process engineers to redesign HVAC systems and reduce transfer steps between wet and dry milling. Manufacturers have documented crystalline transformation during high-shear granulation—hence current process qualification tends to emphasize robust polymorph control and real-time XRD monitoring. Introduction of quality-by-design and near-infrared spectroscopy at capsule filling provides faster in-process control, reducing risk of blend segregation.
Market expansion for levofloxacin hydrochloride capsules largely corresponds to antimicrobial stewardship policies and resistance monitoring data in hospitals. The oral segment expects steady growth, especially in regions with high generic penetration and increased government tendering, though price competition requires ongoing cost optimization. Local regulatory tightening over residual genotoxic impurities and nitrosamine risk assessment aligns with increased technical barrier for both API synthesis and finished dosage testing.
Recent upgrades in continuous granulation and automated capsule weight-checking have decreased lot variability. Concerted R&D investment in solvent-less API crystallization and green synthesis is likely to shift standard batch protocols. Next-generation manufacturing plants integrate digital batch recording and cloud-based process monitoring, offering real-time root-cause analytics for quality deviations and stronger data integrity for regulatory submission.
Environmental controls drive selection of lower-impact solvents and encourage switch to energy-efficient process routes for API synthesis. Valorization of downstream process streams—such as recovery and reuse of organic solvents—is now included in plant performance metrics. Production management tends to partner with environmental engineers to audit and upgrade effluent treatment, minimizing API residue discharge.
Technical teams answer formulation and analytical method requests from customers, focusing on compatibility of levofloxacin hydrochloride capsules with specific excipient systems, capsule shell types, or packaging materials. Guidance covers dissolution testing, in-use stability conditions, and impurity trending, often tailored to each region’s pharmacopeial standards.
Customers working on combination products or complex drug delivery projects receive batch history data, blending and encapsulation advice, and troubleshooting input for scale-up challenges. Detailed impurity profiles, cross-validation samples, and polymorph comparison data can be provided on request. Plant chemists frequently collaborate with external labs on customer-driven method validation and stability study designs.
Manufacturing support extends to customer complaint handling, batch traceability, document provision for regulatory filings, and technical site visits when operational problems arise. Each supply lot is covered by a defined release protocol rooted in current internal control criteria, in addition to meeting external quality specifications. Any observed variability is managed with direct consultation and root-cause investigation, backed by access to retained samples and comprehensive in-process documentation. Continuous feedback from end users informs ongoing process qualification and product upgrade cycles.
Every batch of Levofloxacin Hydrochloride Capsules passes through our in-house synthesis, encapsulation, and finishing lines. Raw materials undergo a comprehensive raw material verification process and are processed with validated equipment operated by skilled plant technicians. Multiple automated stations handle granulation, dosing, and sealing, with airtight integration across mixing, drying, and capsule filling. All critical steps stay under close supervision from digital monitors and production engineers at each shift. Every operator receives annual retraining aligned with the latest regulatory requirements.
Our Levofloxacin Hydrochloride Capsules serve as key actives for pharmaceutical manufacturers, hospital contract packers, and national drug programs. Formulators depend on the drug’s broad-spectrum bacterial action in respiratory, urinary, and skin infection treatments. Secondary manufacturers specify these capsules to feed automated bottling and blistering operations without interruption. Downstream partners report consistently low deviation rates in filling lines, even during high-throughput campaigns or seasonal demand spikes.
Quality control runs deep in the production system. Each batch faces full-spectrum testing: particle size, water content, assay, dissolution, identity, and microbial load—benchmarked against all listed pharmacopeial standards. Evaluation starts with each lot number’s retention samples, which are archived for up to five years for traceability. Randomized in-process samples undergo rapid HPLC quantification to detect variation before the capsules reach packaging. Onsite QA labs publish full-cohort release certificates before dispatch from our warehouse.
We control every aspect of packaging—polymer-grade capsule shells, moisture-barrier liners, tamper-proof secondary cartons. Finished product leaves the plant in heavy-gauge export cartons fitted for sea, air, or road transit. Our shipping schedules integrate real-time logistics, supporting both just-in-time deliveries and pre-season buffer stock programs. Urgent volumes mobilize from production reserve stock or quick release via validated shipping channels to avoid gaps in customer operations. Orders scale from pilot lots for market launches to year-round bulk supply for institutional buyers.
Technical and regulatory teams engage directly with customers’ development and QA functions. Our technical staff issue product performance reports based on real-time process parameters and stability test data generated in our in-house labs. Industrial partners receive firsthand process feedback, not secondhand vendor notes. Scale-up and tech transfer teams help integrate our capsules into bottle filling and secondary packaging lines, reducing the time from approval to commercial launch.
Pharmaceutical manufacturers, national procurement teams, and distribution groups realize operating gains from our process control. Reliable lot-to-lot consistency cuts rework and rejects in high-speed filling. Every buyer sees the supply reliability born from integrating manufacturing and QA within one site. Large-scale institutional buyers use forecast-driven replenishment slots, ensuring uninterrupted distribution. Our team addresses technical feedback, allowing buyers to streamline risk audits and regulatory inspections on each shipment. This integrated approach supports stable sourcing strategies for public health programs and private drug supply chains.
Levofloxacin hydrochloride is classified as a fluoroquinolone antibiotic, a cornerstone for a wide range of bacterial infections. From a production standpoint, the mechanism driving its success traces back to the molecule’s interaction with bacterial enzymes. Our technical team observes that levofloxacin targets DNA gyrase and topoisomerase IV—two critical components in the bacterial DNA replication and repair machinery. The active ingredient achieves its effects by binding to these enzymes, blocking their ability to properly manage DNA supercoiling and segregation. This disruption impedes bacterial multiplication and leads to cell death. The specificity to bacterial enzymes means the risk of affecting human DNA processes remains minimal, an important consideration that has guided our process design to prevent cross-contamination and maintain highest purity in line with current regulatory expectations.
Our manufacturing protocols focus on reproducibility and absorption, two pillars critical to the therapeutic performance of oral levofloxacin hydrochloride capsules. The oral formulation is crafted for rapid and substantial absorption through the gastrointestinal tract. As a direct producer, we have observed that levofloxacin demonstrates high bioavailability, often exceeding 99 percent in clinical settings. Minimal first-pass metabolism means nearly all the administered dose enters systemic circulation unchanged, contributing to consistent plasma concentrations. In the plant, we maintain controls over particle size and crystalline structure, realizing that these parameters influence dissolution and, ultimately, gastrointestinal absorption.
Diet can influence absorption, especially with dairy products or mineral supplements that may chelate fluoroquinolones and reduce gastrointestinal uptake. For industrial-scale batches, we run rigorous dissolution and absorption studies to confirm batch-to-batch consistency, understanding that healthcare providers rely on predictable pharmacokinetics. Our technical specialists routinely test not just for API assay, but also for excipient interaction and stability, ensuring the product meets stringent international standards.
Levofloxacin’s reliable mechanism of action and high bioavailability explain its medical importance but also present manufacturing challenges. Preventing environmental contamination with fluoroquinolone residues remains critical in our process. We enforce multi-stage purification and in-process monitoring to deliver a product with low impurity levels. With increased attention on antibiotic resistance, we design our production flows to minimize cross-contamination with other antimicrobials and prevent trace residues in waste effluents. We also keep close control over moisture and thermal exposure, since the active ingredient can degrade if handled outside recommended parameters.
As direct producers, we respond to evolving regulatory approaches on antibiotics with ongoing investment in analytical testing, documentation, and validation. Our technical team supports partners with stability data, dissolution profiles, and detailed manufacturing records for regulatory submissions. Demand for levofloxacin hydrochloride capsules spans multiple regions, and we align each batch with regional pharmacopoeial standards. Continuous improvement in granulation, blending, and encapsulation steps supports a finished product that meets provider expectations for both clinical effectiveness and safety.
We remain committed to transparency and traceability in our manufacturing chain, supporting the responsible use of levofloxacin and a global fight against antimicrobial resistance. Detailed specifications and batch documentation are available to all qualified partners.
As the direct manufacturer of Levofloxacin Hydrochloride Capsules, we often address bulk procurement questions from both pharmaceutical companies and institutional buyers. Understanding minimum order quantities and realistic manufacturing timelines forms the foundation for any successful project in this market.
Tablet and capsule manufacturing runs require a certain scale to achieve production efficiency and ensure strict quality control. On our lines, the minimum order quantity for Levofloxacin Hydrochloride Capsules sits at one batch, directly tied to our granulation and encapsulation machinery throughput. This typically equates to tens of thousands of capsules, which covers stability testing, in-process QC, and packaging set-up. Common batch sizes reflect the filling and blistering equipment: for us, this starts at around 100,000 capsules per strength. This figure allows us to optimize costs, workflow, and quality evaluation throughout the process. Lower volumes don't support efficient material handling, risk testing, and FDA-compliant scrutiny.
Obligations such as stability trials, full documentation, serialization, and batch certification all benefit from reliably scaled production. Large customers working with us appreciate clear scheduling and opportunity for strategic inventory planning at this threshold.
From order confirmation, we advise production slots based on the current queue, raw material inventory, and regulatory release requirements. For established product strengths with validated formulation and packaging, our typical lead time runs between 4 to 6 weeks for standard orders. The actual cycle includes sourcing Levofloxacin API, excipient inspection, granulation, encapsulation, drying, blister or bottle packaging, and stability sampling. At the end of the process, full batch records and release testing are completed before dispatch.
If a client requests a new dosage strength, alternative package design, or specific national regulatory filing, lead times can extend—extra weeks going to tech transfer, method validation, or custom packaging changes. We advise these windows upfront so procurement teams can synchronize supply schedules and minimize disruption in their logistics pipeline.
We maintain advance commitments on raw materials, audit production consumables in real time, and work closely with logistics teams to eliminate bottlenecks. Our technical team reviews each order for any unique compliance needs--for example, certain countries require additional stability data or stringent impurity profiling, which may influence the timeline. By managing all production stages internally, we ensure full transparency: clients work directly with the team responsible for manufacturing, not middlemen.
Our operation handles both year-long contract manufacturing and ad-hoc spot orders, supporting clients with clear documentation, Pharmacopoeia compliance, and packed goods matched to market requirements. We balance fast turnaround with batch-level transparency, and always notify buyers early if raw material availability or regulatory conditions suggest a timing adjustment.
For buyers managing changing demand or multiple destination markets, early coordination and accurate forecasts help mitigate pressures along the supply chain. When the time comes for batch release, samples, or data submission, our in-house regulatory and quality teams offer direct support. We back every bulk order with the experience, process control, and technical insight of a full-scale pharmaceutical manufacturer.
Levofloxacin Hydrochloride Capsules require careful attention from the manufacturing stage all the way to shipment. Our capsules leave the factory only after stability studies confirm the best conditions for maintaining their quality. In our experience, temperature and humidity have an immediate impact on capsule hardening, discoloration, or reduced potency. We store our finished capsules in a controlled environment, usually between 20°C–25°C. Our storage rooms operate with humidity well below 60% to limit any moisture ingress.
Strict packaging and batch segregation protect capsules from light. We only use light-resistant, tamper-evident containers underlined with double-sealed liners. This approach not only helps maintain the chemical stability but meets the shipment conditions expected by leading regulators.
Manufacturers shipping Levofloxacin Hydrochloride Capsules across borders face a complex regulatory map. Every export batch, before dispatch, runs through our quality assurance protocols tied to Good Manufacturing Practices. Our production facilities maintain GMP certification by recognized drug authorities such as the US FDA or European agencies, audited for traceability, sanitation, environmental monitoring, and batch release management.
International shipments typically require a Certificate of Analysis (COA) for each lot, reflecting rigorous in-house and independent testing. Our COAs include assay, impurity profile, dissolution, and uniformity analyses. For destination markets, we accompany every consignment with a Drug Master File (DMF) or equivalent technical file to support local regulatory filings.
Shipping documentation extends to specific regulatory export certificates, including but not limited to Certificates of Pharmaceutical Product (COPP), and declarations for compliance with ICH guidelines where relevant. Depending on the destination, we supply a GMP certificate recognized by the target country’s health agency.
From our perspective as the manufacturer, the journey from plant to port involves more than paperwork. For sensitive cargo, we use validated, insulated packaging that limits exposure to out-of-range temperatures. We log environmental conditions during transit with data loggers inside each consignment—often a prerequisite for regulatory clearances and subsequent release at customs.
In markets with specific standards, such as EU GDP (Good Distribution Practice), we work closely with logistics partners to uphold those standards throughout the supply chain. Direct manufacturer involvement shortens response times should rerouting or reconditioning be needed, especially at critical handoff points like customs warehouses or airport tarmacs.
We periodically review stability data from retained samples and work actively with our technical team to update label claims or packaging specifications if regulatory bodies request additional precautions—such as temperature excursion protocols or change in primary packaging.
As the original manufacturer, our commitment extends beyond legal obligations. We keep internal and external audits thorough, and our QA staff receives ongoing training based on the latest pharmacopoeia revisions and compliance standards. We treat every international shipment as a representation of our entire production process; each batch carries the full stamp of our manufacturing and compliance system.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
